Does the media prefer AURA or TNXP?

In the previous week, Tonix Pharmaceuticals had 2 more articles in the media than Aura Biosciences. MarketBeat recorded 4 mentions for Tonix Pharmaceuticals and 2 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 0.37 beat Tonix Pharmaceuticals' score of 0.20 indicating that Aura Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aura Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tonix Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor TNXP or CLYM?

In the previous week, Climb Bio had 1 more articles in the media than Tonix Pharmaceuticals. MarketBeat recorded 5 mentions for Climb Bio and 4 mentions for Tonix Pharmaceuticals. Climb Bio's average media sentiment score of 0.47 beat Tonix Pharmaceuticals' score of 0.20 indicating that Climb Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tonix Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Climb Bio 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ACRS or TNXP?

In the previous week, Aclaris Therapeutics had 1 more articles in the media than Tonix Pharmaceuticals. MarketBeat recorded 5 mentions for Aclaris Therapeutics and 4 mentions for Tonix Pharmaceuticals. Tonix Pharmaceuticals' average media sentiment score of 0.20 beat Aclaris Therapeutics' score of -0.04 indicating that Tonix Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Tonix Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor TNXP or IRWD?

In the previous week, Tonix Pharmaceuticals had 1 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 4 mentions for Tonix Pharmaceuticals and 3 mentions for Ironwood Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 0.42 beat Tonix Pharmaceuticals' score of 0.20 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tonix Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ironwood Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CTMX or TNXP?

In the previous week, Tonix Pharmaceuticals had 1 more articles in the media than CytomX Therapeutics. MarketBeat recorded 4 mentions for Tonix Pharmaceuticals and 3 mentions for CytomX Therapeutics. Tonix Pharmaceuticals' average media sentiment score of 0.20 beat CytomX Therapeutics' score of -0.63 indicating that Tonix Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Tonix Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Tonix Pharmaceuticals (TNXP) Competitors

$7.30 +0.02 (+0.27%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$7.31 +0.01 (+0.14%)

As of 10/9/2026 07:59 PM Eastern

Compare

TNXP vs. AURA, CLYM, ACRS, IRWD, and CTMX

Should you buy Tonix Pharmaceuticals stock or one of its competitors? Tonix Pharmaceuticals's main competitors and comparable companies include Aura Biosciences (AURA), Climb Bio (CLYM), Aclaris Therapeutics (ACRS), Ironwood Pharmaceuticals (IRWD), and CytomX Therapeutics (CTMX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Tonix Pharmaceuticals compare to Aura Biosciences?

Aura Biosciences (NASDAQ:AURA) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.

Aura Biosciences has higher earnings, but lower revenue than Tonix Pharmaceuticals. Aura Biosciences is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.75	N/A
Tonix Pharmaceuticals	$13.11M	9.55	-$124.02M	-$12.94	N/A

96.8% of Aura Biosciences shares are held by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are held by institutional investors. 1.9% of Aura Biosciences shares are held by insiders. Comparatively, 2.0% of Tonix Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Aura Biosciences has a beta of 0.41, indicating that its stock price is 59% less volatile than the broader market. Comparatively, Tonix Pharmaceuticals has a beta of 1.78, indicating that its stock price is 78% more volatile than the broader market.

Aura Biosciences has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -548.64%. Tonix Pharmaceuticals' return on equity of -68.99% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-73.18%	-62.00%
Tonix Pharmaceuticals	-548.64%	-68.99%	-61.31%

Aura Biosciences presently has a consensus price target of $17.50, suggesting a potential upside of 167.58%. Tonix Pharmaceuticals has a consensus price target of $24.50, suggesting a potential upside of 235.62%. Given Tonix Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Tonix Pharmaceuticals is more favorable than Aura Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Tonix Pharmaceuticals had 2 more articles in the media than Aura Biosciences. MarketBeat recorded 4 mentions for Tonix Pharmaceuticals and 2 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 0.37 beat Tonix Pharmaceuticals' score of 0.20 indicating that Aura Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aura Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tonix Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Tonix Pharmaceuticals beats Aura Biosciences on 10 of the 16 factors compared between the two stocks.

How does Tonix Pharmaceuticals compare to Climb Bio?

Tonix Pharmaceuticals (NASDAQ:TNXP) and Climb Bio (NASDAQ:CLYM) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Climb Bio has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -548.64%. Climb Bio's return on equity of -31.79% beat Tonix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tonix Pharmaceuticals	-548.64%	-68.99%	-61.31%
Climb Bio	N/A	-31.79%	-30.79%

In the previous week, Climb Bio had 1 more articles in the media than Tonix Pharmaceuticals. MarketBeat recorded 5 mentions for Climb Bio and 4 mentions for Tonix Pharmaceuticals. Climb Bio's average media sentiment score of 0.47 beat Tonix Pharmaceuticals' score of 0.20 indicating that Climb Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tonix Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Climb Bio	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tonix Pharmaceuticals currently has a consensus price target of $24.50, suggesting a potential upside of 235.62%. Climb Bio has a consensus price target of $27.62, suggesting a potential upside of 151.05%. Given Tonix Pharmaceuticals' higher probable upside, research analysts plainly believe Tonix Pharmaceuticals is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

Climb Bio has lower revenue, but higher earnings than Tonix Pharmaceuticals. Climb Bio is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tonix Pharmaceuticals	$13.11M	9.55	-$124.02M	-$12.94	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.83	N/A

82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. Comparatively, 69.8% of Climb Bio shares are owned by institutional investors. 2.0% of Tonix Pharmaceuticals shares are owned by company insiders. Comparatively, 2.6% of Climb Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Tonix Pharmaceuticals has a beta of 1.78, meaning that its stock price is 78% more volatile than the broader market. Comparatively, Climb Bio has a beta of -0.04, meaning that its stock price is 104% less volatile than the broader market.

Summary

Climb Bio beats Tonix Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Tonix Pharmaceuticals compare to Aclaris Therapeutics?

Aclaris Therapeutics (NASDAQ:ACRS) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.

Aclaris Therapeutics has higher earnings, but lower revenue than Tonix Pharmaceuticals. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	68.39	-$64.92M	-$0.58	N/A
Tonix Pharmaceuticals	$13.11M	9.55	-$124.02M	-$12.94	N/A

Tonix Pharmaceuticals has a net margin of -548.64% compared to Aclaris Therapeutics' net margin of -921.50%. Aclaris Therapeutics' return on equity of -61.65% beat Tonix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-921.50%	-61.65%	-42.41%
Tonix Pharmaceuticals	-548.64%	-68.99%	-61.31%

In the previous week, Aclaris Therapeutics had 1 more articles in the media than Tonix Pharmaceuticals. MarketBeat recorded 5 mentions for Aclaris Therapeutics and 4 mentions for Tonix Pharmaceuticals. Tonix Pharmaceuticals' average media sentiment score of 0.20 beat Aclaris Therapeutics' score of -0.04 indicating that Tonix Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclaris Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tonix Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aclaris Therapeutics presently has a consensus price target of $11.33, suggesting a potential upside of 195.91%. Tonix Pharmaceuticals has a consensus price target of $24.50, suggesting a potential upside of 235.62%. Given Tonix Pharmaceuticals' higher probable upside, analysts clearly believe Tonix Pharmaceuticals is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00

98.3% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. 4.8% of Aclaris Therapeutics shares are owned by company insiders. Comparatively, 2.0% of Tonix Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Aclaris Therapeutics has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market. Comparatively, Tonix Pharmaceuticals has a beta of 1.78, suggesting that its stock price is 78% more volatile than the broader market.

Summary

Aclaris Therapeutics beats Tonix Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Tonix Pharmaceuticals compare to Ironwood Pharmaceuticals?

Tonix Pharmaceuticals (NASDAQ:TNXP) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

In the previous week, Tonix Pharmaceuticals had 1 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 4 mentions for Tonix Pharmaceuticals and 3 mentions for Ironwood Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 0.42 beat Tonix Pharmaceuticals' score of 0.20 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tonix Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ironwood Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tonix Pharmaceuticals currently has a consensus price target of $24.50, suggesting a potential upside of 235.62%. Ironwood Pharmaceuticals has a consensus price target of $6.23, suggesting a potential upside of 63.18%. Given Tonix Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Tonix Pharmaceuticals is more favorable than Ironwood Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00
Ironwood Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.57

Ironwood Pharmaceuticals has higher revenue and earnings than Tonix Pharmaceuticals. Tonix Pharmaceuticals is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tonix Pharmaceuticals	$13.11M	9.55	-$124.02M	-$12.94	N/A
Ironwood Pharmaceuticals	$296.15M	2.13	$24.02M	$0.77	4.96

Tonix Pharmaceuticals has a beta of 1.78, suggesting that its stock price is 78% more volatile than the broader market. Comparatively, Ironwood Pharmaceuticals has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market.

82.3% of Tonix Pharmaceuticals shares are held by institutional investors. 2.0% of Tonix Pharmaceuticals shares are held by insiders. Comparatively, 9.3% of Ironwood Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Ironwood Pharmaceuticals has a net margin of 33.36% compared to Tonix Pharmaceuticals' net margin of -548.64%. Ironwood Pharmaceuticals' return on equity of -58.38% beat Tonix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tonix Pharmaceuticals	-548.64%	-68.99%	-61.31%
Ironwood Pharmaceuticals	33.36%	-58.38%	34.93%

Summary

Ironwood Pharmaceuticals beats Tonix Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Tonix Pharmaceuticals compare to CytomX Therapeutics?

CytomX Therapeutics (NASDAQ:CTMX) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

CytomX Therapeutics has a beta of 2.21, indicating that its share price is 121% more volatile than the broader market. Comparatively, Tonix Pharmaceuticals has a beta of 1.78, indicating that its share price is 78% more volatile than the broader market.

In the previous week, Tonix Pharmaceuticals had 1 more articles in the media than CytomX Therapeutics. MarketBeat recorded 4 mentions for Tonix Pharmaceuticals and 3 mentions for CytomX Therapeutics. Tonix Pharmaceuticals' average media sentiment score of 0.20 beat CytomX Therapeutics' score of -0.63 indicating that Tonix Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Tonix Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CytomX Therapeutics has a net margin of -435.21% compared to Tonix Pharmaceuticals' net margin of -548.64%. CytomX Therapeutics' return on equity of -38.46% beat Tonix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-435.21%	-38.46%	-30.33%
Tonix Pharmaceuticals	-548.64%	-68.99%	-61.31%

CytomX Therapeutics presently has a consensus target price of $11.90, indicating a potential upside of 363.04%. Tonix Pharmaceuticals has a consensus target price of $24.50, indicating a potential upside of 235.62%. Given CytomX Therapeutics' higher probable upside, research analysts plainly believe CytomX Therapeutics is more favorable than Tonix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00

67.8% of CytomX Therapeutics shares are held by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are held by institutional investors. 3.8% of CytomX Therapeutics shares are held by insiders. Comparatively, 2.0% of Tonix Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

CytomX Therapeutics has higher revenue and earnings than Tonix Pharmaceuticals. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$76.20M	7.35	-$17.37M	-$0.50	N/A
Tonix Pharmaceuticals	$13.11M	9.55	-$124.02M	-$12.94	N/A

Summary

CytomX Therapeutics beats Tonix Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

Get Tonix Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TNXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TNXP vs. The Competition

Export

Metric	Tonix Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$124.86M	$3.85B	$7.16B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	16.37%
P/E Ratio	-0.56	13.42	274.15	26.16
Price / Sales	4.30	1,234.34	635.97	113.01
Price / Cash	N/A	116.56	76.38	53.09
Price / Book	0.38	17.17	11.21	6.34
Net Income	-$124.02M	-$22.69M	$3.50B	$381.90M
7 Day Performance	-18.07%	-1.33%	-0.90%	-1.41%
1 Month Performance	-40.55%	-8.44%	-4.44%	-3.48%
1 Year Performance	-65.55%	14.02%	6.96%	1.16%

Tonix Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TNXP Tonix Pharmaceuticals	3.6218 of 5 stars	$7.30 +0.3%	$24.50 +235.6%	-67.6%	$124.86M	$29.10M	N/A	142
AURA Aura Biosciences	2.0059 of 5 stars	$6.05 +0.1%	$17.50 +189.5%	+8.5%	$627.86M	N/A	N/A	113
CLYM Climb Bio	2.4696 of 5 stars	$10.86 -1.9%	$26.92 +147.9%	+482.0%	$623.22M	N/A	N/A	29
ACRS Aclaris Therapeutics	1.9424 of 5 stars	$4.34 -1.7%	$11.33 +161.4%	+96.4%	$608.92M	$7.83M	N/A	73	News Coverage
IRWD Ironwood Pharmaceuticals	3.0823 of 5 stars	$3.65 -3.1%	$6.23 +71.0%	+115.8%	$602.30M	$296.15M	4.73	100	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TNXP) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tonix Pharmaceuticals (TNXP) Competitors

TNXP vs. AURA, CLYM, ACRS, IRWD, and CTMX

How does Tonix Pharmaceuticals compare to Aura Biosciences?

Summary

How does Tonix Pharmaceuticals compare to Climb Bio?

Summary

How does Tonix Pharmaceuticals compare to Aclaris Therapeutics?

Summary

How does Tonix Pharmaceuticals compare to Ironwood Pharmaceuticals?

Summary

How does Tonix Pharmaceuticals compare to CytomX Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNXP vs. The Competition

Tonix Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tonix Pharmaceuticals (TNXP) Competitors

TNXP vs. AURA, CLYM, ACRS, IRWD, and CTMX

How does Tonix Pharmaceuticals compare to Aura Biosciences?

Which has stronger earnings and valuation, AURA or TNXP?

Do insiders and institutionals have more ownership in AURA or TNXP?

Which has more risk and volatility, AURA or TNXP?

Is AURA or TNXP more profitable?

Do analysts rate AURA or TNXP?

Does the media prefer AURA or TNXP?

Summary

How does Tonix Pharmaceuticals compare to Climb Bio?

Is TNXP or CLYM more profitable?

Does the media favor TNXP or CLYM?

Do analysts prefer TNXP or CLYM?

Which has preferable earnings and valuation, TNXP or CLYM?

Do institutionals and insiders hold more shares of TNXP or CLYM?

Which has more risk and volatility, TNXP or CLYM?

Summary

How does Tonix Pharmaceuticals compare to Aclaris Therapeutics?

Which has higher valuation and earnings, ACRS or TNXP?

Is ACRS or TNXP more profitable?

Does the media prefer ACRS or TNXP?

Do analysts prefer ACRS or TNXP?

Do institutionals & insiders have more ownership in ACRS or TNXP?

Which has more risk & volatility, ACRS or TNXP?

Summary

How does Tonix Pharmaceuticals compare to Ironwood Pharmaceuticals?

Does the media favor TNXP or IRWD?

Do analysts recommend TNXP or IRWD?

Which has better valuation and earnings, TNXP or IRWD?

Which has more volatility & risk, TNXP or IRWD?

Do insiders and institutionals hold more shares of TNXP or IRWD?

Is TNXP or IRWD more profitable?

Summary

How does Tonix Pharmaceuticals compare to CytomX Therapeutics?

Which has more volatility & risk, CTMX or TNXP?

Does the media refer more to CTMX or TNXP?

Is CTMX or TNXP more profitable?

Do analysts prefer CTMX or TNXP?

Do insiders & institutionals have more ownership in CTMX or TNXP?

Which has stronger valuation & earnings, CTMX or TNXP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNXP vs. The Competition

Tonix Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools